Faecal transplantation for IBD management-pitfalls and promises
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
- Department of Gastroenterology, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK.
Background: Faecal microbiota transplantation (FMT) as a potential treatment for inflammatory bowel disease (IBD) is an area of active current research, having been stimulated by the remarkable efficacy of FMT in treatment of Clostridium difficile-associated colitis.
Sources of data: This review is based on data from numerous case series on FMT in IBD since 1989 and results of four RCTs in ulcerative colitis (UC); three fully published.
Areas of agreement: Early signals of short to medium-term efficacy of FMT for UC are promising.
Areas of controversy: Methodology, underlying mechanisms and questions regarding safety of FMT remain controversial.
Growing points: Many trials of FMT in adults and children are currently recruiting.
Areas timely for developing research: Future trials of FMT will likely revisit Crohn's disease and patients undergoing pouch surgery. Advances in microbial culture complementing genetic sequencing and investigations into the virome and mycobiome in IBD will be of great future interest.
|Number of pages||10|
|Journal||British Medical Bulletin|
|Early online date||13 Nov 2017|
|Publication status||Published - 1 Dec 2017|
- Evidence-Based Medicine, Fecal Microbiota Transplantation/methods, Gastrointestinal Microbiome/immunology, Humans, Inflammatory Bowel Diseases/immunology, Randomized Controlled Trials as Topic, Remission Induction, Treatment Outcome